Biblio
Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to whites: a propensity-score matched analysis. Am J Hematol. 2021.
Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv. 2020;4(19):4834-4837.
HLA Factors Versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther. 2022.
Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019.
Melphalan based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. 2018.
Myeloablative Fractionated Busulfan for Allogeneic Stem Cell Transplant in Older Patients or Patients with Comorbidities. Blood Adv. 2023.
Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther. 2021.